SCHEMBL832668

SCHEMBL832668

Cc1ccc(OCCn2c(C(=O)Nc3ccc4c(c3)nc3n4CCC3)cc3cc(F)ccc32)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.41
TP53 P04637 7/20 0.41
ALDH1A1 P00352 6/20 0.41
USP2 O75604 4/20 0.41
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
APP P05067 1/20 0.40
LMNA P02545 5/20 0.40
KDM4E B2RXH2 5/20 0.40
HSD17B10 Q99714 4/20 0.40
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
GFER P55789 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL832122 0.91 MEN1 (0.41) MAPTTP53ALDH1A1USP2RAB9A
SCHEMBL832026 0.82 TP53 (0.44) MAPTTP53ALDH1A1USP2RAB9A
SCHEMBL832123 0.81 ALDH1A1 (0.42) MAPTTP53ALDH1A1USP2RAB9A
SCHEMBL840177 0.80 APP (0.49) MAPTTP53ALDH1A1USP2RAB9A
SCHEMBL833715 0.78 RAB9A (0.47) MAPTTP53ALDH1A1USP2RAB9A
SCHEMBL832828 0.78 APP (0.44) MAPTTP53ALDH1A1USP2RAB9A
SCHEMBL831540 0.76 LMNA (0.45) MAPTTP53ALDH1A1USP2RAB9A
SCHEMBL829962 0.76 RAB9A (0.50) MAPTTP53ALDH1A1USP2RAB9A
SCHEMBL3114834 0.76 ALDH1A1 (0.50) TP53ALDH1A1LMNAKDM4EHSD17B10
SCHEMBL830576 0.74 NOD2 (0.45) MAPTALDH1A1LMNAKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288376-B2 Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use SANOFI (FR) 2012-10-16 US disclosed
US-20120122852-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE SANOFI-AVENTIS (FR) 2012-05-17 US disclosed
US-8143248-B2 Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use SANOFI-AVENTIS (FR) 2012-03-27 US disclosed
EP-1987010-B1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE SANOFI AVENTIS (FR) 2010-04-07 EP disclosed
US-20090042873-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE SANOFI-AVENTIS (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122852-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE CYP3A5, CYP2C8, CYP3A43 MAPT 3000/4885TP53 3698/4885ALDH1A1 453/4885
US-20090042873-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE CYP3A5, CYP2C8, PAICS MAPT 3347/4885TP53 3752/4885ALDH1A1 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.